Abdul Mannan: The Dual Biology of the Sickle Cell Mutation
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn about an article by Gavin Band et al. published in Nature, adding:
“The sickle mutation is not simply ‘protective’.
It depends on whether you inherit one copy or two.
That is the whole paradox.
Here’s the simple version:
- HbAS protects because the parasite creates local hypoxia inside the red cell
- That triggers limited HbS polymerisation
- The infected red cell sickles
- A working spleen clears it, parasite included
- Less PfEMP1 reaches the cell surface, so there is less adhesion and rosetting
But HbSS is different:
- The spleen is often lost early through repeated infarction
- Red cells are already under sickling stress
- There is no HbA buffer
- Baseline anaemia leaves little reserve
- Malaria then adds haemolysis on top of haemolysis
So the same mutation can act like a trap in HbAS, but becomes a liability in HbSS.
A 2022 Nature paper by Band et al. added another layer: HbS protection also depends on parasite genotype, with Pfsa1, Pfsa2 and Pfsa3 loci linked to parasites that can cause severe malaria despite HbS.
For trainees, this is a beautiful teaching point:
Genetics is never isolated from environment.
And malaria wrote part of the sickle cell story.
What is your favourite example of evolution shaping haematology?”
Title: Malaria protection due to sickle haemoglobin depends on parasite genotype
Authors: Gavin Band, Ellen M. Leffler, Muminatou Jallow, Fatoumatta Sisay-Joof, Carolyne M. Ndila, Alexander W. Macharia, Christina Hubbart, Anna E. Jeffreys, Kate Rowlands, Thuy Nguyen, Sónia Gonçalves, Cristina V. Ariani, Jim Stalker, Richard D. Pearson, Roberto Amato, Eleanor Drury, Giorgio Sirugo, Umberto d’Alessandro, Kalifa A. Bojang, Kevin Marsh, Norbert Peshu, Joseph W. Saelens, Mahamadou Diakité, Steve M. Taylor, David J. Conway, Thomas N. Williams, Kirk A. Rockett, Dominic P. Kwiatkowski
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Jun 28, 2026, 19:05Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
-
Jun 28, 2026, 19:05Pinar Demirtepe: Not All “Blood Thinners” Are the Same
-
Jun 28, 2026, 19:05Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
-
Jun 28, 2026, 19:02Nassim Emteir: Interpreting TSAT with Ferritin to Guide Iron Deficiency Diagnosis and Treatment
-
Jun 28, 2026, 19:00Andrew Jackson: Predicting PICC-Related Venous Thrombosis in Patients Undergoing Radiotherapy
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients